Modality
ADC
MOA
Menini
Target
PSMA
Pathway
DDR
HCC
Development Pipeline
Preclinical
~Nov 2017
→ ~Feb 2019
Phase 1
~May 2019
→ ~Aug 2020
Phase 2
~Nov 2020
→ ~Feb 2022
Phase 3
~May 2022
→ ~Aug 2023
NDA/BLA
Nov 2023
→ May 2031
NDA/BLACurrent
NCT08170858
974 pts·HCC
2023-11→2031-05·Recruiting
974 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-05-085.1y awayPh3 Readout· HCC
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2031-05-08 · 5.1y away
HCC
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08170858 | NDA/BLA | HCC | Recruiting | 974 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Doxacagene | Sanofi | Approved | PSMA | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| BGN-3859 | BeiGene | Approved | PSMA | |
| Olpafutibatinib | Immunocore | Approved | SMN2 |